Safety of Metformin in Patients with Chronic Obstructive Pulmonary Disease and Type 2 Diabetes Mellitus

References

• Wells CE, Baker EH. Metabolic syndrome and diabetes mellitus in COPD. In: Rabe KF, Wedzicha JA, Wouters EF, editors. European Respiratory Monograph COPD and Comorbidity. 59. Sheffield, UK: European Respiratory Society Journals Ltd., 2013.
   Google Scholar
• Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32(4):962–969.
   PubMed Web of Science ®Google Scholar
• Kinney GL, Black-Shinn JL, Wan ES, Make B, Regan E, Lutz S, et al. Pulmonary Function Reduction in Diabetes Mellitus with and without Chronic Obstructive Pulmonary Disease. Diabetes Care 2014; 37:389–395.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of Medical Care in Diabetes—2013. Diabetes Care 2013; 36(Supplement 1):S11–S66.
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Chronic Conditions (UK). Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update). London: Royal College of Physicians of London, 2008. Available from: http://www.ncbi.nlm.nih.gov/books/NBK53885/.
   Google Scholar
• Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359(15):1577–1589.
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Grant PJ, Evans M, De Fine Olivarius N, Andreasen A, Fowler P, et al. The UK prospective diabetes study. Lancet 1998; 352(9144):1932–1934.
   PubMed Web of Science ®Google Scholar
• Sexton P, Metcalf P, Kolbe J. Respiratory effects of insulin sensitisation with metformin: A prospective observational study. COPD: Journal of Chronic Obstructive Pulmonary Disease 2014; 11:133–142.
   Web of Science ®Google Scholar
• Kim HJ, Lee JY, Jung HS, Kim DK, Lee SM, Yim JJ, et al. The impact of insulin sensitisers on lung function in patients with chronic obstructive pulmonary disease and diabetes. Int J Tuberc Lung Dis 2010; 14(3):362–367.
   PubMed Web of Science ®Google Scholar
• Huang NL, Chiang SH, Hsueh CH, Liang YJ, Chen YJ, Lai LP. Metformin inhibits TNF-alpha-induced IkappaB kinase phosphorylation, IkappaB-alpha degradation and IL-6 production in endothelial cells through PI3K-dependent AMPK phosphorylation. Int J Cardiol 2009; 134(2):169–175.
   PubMed Web of Science ®Google Scholar
• Isoda K, Young JL, Zirlik A, MacFarlane LA, Tsuboi N, Gerdes N, et al. Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler Thromb Vasc Biol 2006; 26(3):611–617.
   PubMed Web of Science ®Google Scholar
• Myerburg MM, King JD, Jr., Oyster NM, Fitch AC, Magill A, Baty CJ, et al. AMPK agonists ameliorate sodium and fluid transport and inflammation in cystic fibrosis airway epithelial cells. Am J Respir Cell Mol Biol 2010; 42(6):676–684.
   PubMed Web of Science ®Google Scholar
• Formoso G, De Filippis EA, Michetti N, Di Fulvio P, Pandolfi A, Bucciarelli T, et al. Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects. Diabetes Metab Res Rev 2008; 24(3):231–237.
   PubMed Web of Science ®Google Scholar
• Bonnefont-Rousselot D, Raji B, Walrand S, Gardes-Albert M, Jore D, Legrand A, et al. An intracellular modulation of free radical production could contribute to the beneficial effects of metformin towards oxidative stress. Metabolism 2003; 52(5):586–589.
   PubMed Web of Science ®Google Scholar
• Garnett JP, Baker EH, Naik S, Lindsay JA, Knight GM, Gill S, et al. Metformin reduces airway glucose permeability and hyperglycaemia-induced Staphylococcus aureus load independently of effects on blood glucose. Thorax. 2013;68(9):835–845.
   PubMed Web of Science ®Google Scholar
• British National Formulary (online). London: BMJ Group and Pharmaceutical Press; 2013. Available from: http://www.bnf.org/bnf/index.htm.
   Google Scholar
• Bristol-Myers Squibb Company. Glucophage (metformin hydrochloride) tablets package insert, Princeton, NJ, USA, 2009. Available from: http://packageinserts.bms.com/pi/pi_glucophage.pdf.
   Google Scholar
• Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010(4). doi: 10.1002/14651858.CD002967.pub4.
   Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40(5):373–383.
   PubMedGoogle Scholar
• Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13(10):818–829.
   PubMed Web of Science ®Google Scholar
• Mongraw-Chaffin ML, Matsushita K, Brancati FL, Astor BC, Coresh J, Crawford SO, et al. Diabetes medication use and blood lactate level among participants with type 2 diabetes: the atherosclerosis risk in communities carotid MRI study. PLoS ONE 2012; 7(12):e51237.
   Web of Science ®Google Scholar
• Davis TM, Jackson D, Davis WA, Bruce DG, Chubb P. The relationship between metformin therapy and the fasting plasma lactate in type 2 diabetes: The Fremantle Diabetes Study. Br J Clin Pharmacol 2001; 52(2):137–144.
   PubMed Web of Science ®Google Scholar
• Dykens JA, Jamieson J, Marroquin L, Nadanaciva S, Billis PA, Will Y. Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitro. Toxicol Appl Pharmacol 2008; 233(2):203–210.
   PubMed Web of Science ®Google Scholar
• Rachmani R, Slavachevski I, Levi Z, Zadok B, Kedar Y, Ravid M. Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications. Eur J Intern Med 2002; 13(7):428.
   PubMedGoogle Scholar
• Hallin R, Gudmundsson G, Suppli Ulrik C, Nieminen MM, Gislason T, Lindberg E, et al. Nutritional status and long-term mortality in hospitalised patients with chronic obstructive pulmonary disease (COPD). Respir Med 2007; 101(9):1954–1960.
   PubMed Web of Science ®Google Scholar